Lei Diao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10388494/publications.pdf

Version: 2024-02-01

10	416	9	10
papers	citations	h-index	g-index
10	10	10	733
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology. Current Pharmacology Reports, 2018, 4, 285-291.	3.0	7
2	Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I–III Clinical Trials. Clinical Pharmacokinetics, 2016, 55, 943-955.	3 . 5	18
3	Tools for predicting the PK/PD of therapeutic proteins. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1115-1125.	3.3	21
4	Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Correlations of Therapeutic Peptides. Clinical Pharmacokinetics, 2013, 52, 855-868.	3.5	233
5	A Substrate Pharmacophore for the Human Organic Cation/Carnitine Transporter Identifies Compounds Associated with Rhabdomyolysis. Molecular Pharmaceutics, 2012, 9, 905-913.	4.6	16
6	Synthesis and in vitro characterization of drug conjugates of l-carnitine as potential prodrugs that target human Octn2. Journal of Pharmaceutical Sciences, 2011, 100, 3802-3816.	3.3	16
7	Quantitative Structure Activity Relationship for Inhibition of Human Organic Cation/Carnitine Transporter. Molecular Pharmaceutics, 2010, 7, 2120-2131.	4.6	31
8	Why we should be vigilant: Drug cytotoxicity observed with in vitro transporter inhibition studies. Biochemical Pharmacology, 2010, 80, 1087-1092.	4.4	11
9	Uptake of Pramipexole by Human Organic Cation Transporters. Molecular Pharmaceutics, 2010, 7, 1342-1347.	4.6	27
10	Novel Inhibitors of Human Organic Cation/Carnitine Transporter (hOCTN2) via Computational Modeling and In Vitro Testing. Pharmaceutical Research, 2009, 26, 1890-1900.	3.5	36